Bristol-Myers Squibb Stock Price, News & Analysis (NYSE:BMY)

$63.43 0.15 (0.24 %)
(As of 01/24/2018 04:40 AM ET)
Previous Close$63.28
Today's Range$62.80 - $63.68
52-Week Range$46.01 - $66.10
Volume6.46 million shs
Average Volume7.14 million shs
Market Capitalization$103.82 billion
P/E Ratio24.97
Dividend Yield2.57%
Beta1.18

About Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb logoBristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNYSE:BMY
CUSIP11012210
Phone+1-212-5464000

Debt

Debt-to-Equity Ratio0.47%
Current Ratio1.59%
Quick Ratio1.46%

Price-To-Earnings

Trailing P/E Ratio24.9724409448819
Forward P/E Ratio21.21
P/E Growth2.16

Sales & Book Value

Annual Sales$19.43 billion
Price / Sales5.34
Cash Flow$3.13 per share
Price / Cash20.28
Book Value$9.78 per share
Price / Book6.49

Profitability

Trailing EPS$2.54
Net Income$4.46 billion
Net Margins16.29%
Return on Equity22.99%
Return on Assets10.19%

Miscellaneous

Employees25,000
Outstanding Shares1,636,700,000

Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb announced a quarterly dividend on Thursday, December 7th. Investors of record on Friday, January 5th will be given a dividend of $0.40 per share on Thursday, February 1st. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date of this dividend is Thursday, January 4th. This is an increase from Bristol-Myers Squibb's previous quarterly dividend of $0.39. View Bristol-Myers Squibb's Dividend History.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb Co (NYSE:BMY) announced its earnings results on Thursday, October, 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by $0.02. The biopharmaceutical company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a net margin of 16.29% and a return on equity of 22.99%. The business's revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.77 earnings per share. View Bristol-Myers Squibb's Earnings History.

When will Bristol-Myers Squibb make its next earnings announcement?

Bristol-Myers Squibb is scheduled to release their next quarterly earnings announcement on Monday, February, 5th 2018. View Earnings Estimates for Bristol-Myers Squibb.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb issued an update on its FY17 earnings guidance on Thursday, October, 26th. The company provided earnings per share guidance of $2.95-3.05 for the period, compared to the Thomson Reuters consensus estimate of $2.96.

Where is Bristol-Myers Squibb's stock going? Where will Bristol-Myers Squibb's stock price be in 2018?

16 brokerages have issued twelve-month price targets for Bristol-Myers Squibb's stock. Their predictions range from $52.00 to $75.00. On average, they expect Bristol-Myers Squibb's stock price to reach $65.00 in the next year. View Analyst Ratings for Bristol-Myers Squibb.

What are Wall Street analysts saying about Bristol-Myers Squibb stock?

Here are some recent quotes from research analysts about Bristol-Myers Squibb stock:

  • 1. According to Zacks Investment Research, "Bristol-Myers’ blockbuster drug Opdivo is facing competitive challenges in the United States. With the FDA approving Merck’s Keytruda, for the first-line treatment of metastatic non-squamous NSCLC, the competition will stiffen up.  Pricing concerns, stiff competition in the HCV and immuno-oncology space are expected to remain a significant overhang on the company’s shares. Yervoy’s sales are expected to be under pressure due to adoption of Opdivo in adjuvant melanoma. Gross margin is also expected to be under pressure due to product mix and declines in virology business. Shares of the company have underperformed the industry in the last twelve months. Estimates have remained stable ahead of Q4 earnings. The company has a mixed record of earnings surprises in the recent quarters." (1/19/2018)
  • 2. Robert W. Baird analysts commented, "The broader opportunity for 2125, theoretically, is it could be used in many different tumor types and many different cancer indications." (4/25/2017)
  • 3. Jefferies Group LLC analysts commented, "Management seems to have scared investors out of the stock by saying they were "committed to" rather than confident on the Opdivo/ Yervoy combo. We see the guidance cut as a casualty of the new era of conservatism at BMY, though the market seems convinced MRK will get KN-021(G) approved by May anyway. We see a potential acquisition of BMY as increasingly likely as the stock moves towards our ex-lung valuation of $44." (1/27/2017)

Who are some of Bristol-Myers Squibb's key competitors?

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the folowing people:

  • Giovanni Caforio M.D., Chairman of the Board, Chief Executive Officer (Age 52)
  • Charles A. Bancroft, Chief Financial Officer and Executive Vice President - Global Business Operations (Age 57)
  • Louis S. Schmukler, President - Global Manufacturing and Supply (Age 61)
  • Ann Powell Judge, Chief Human Resource Officer, Senior Vice President (Age 51)
  • Thomas J. Lynch Jr., M.D., Ph.D., Executive Vice President, Chief Scientific Officer (Age 56)
  • Sandra Leung, Executive Vice President, General Counsel (Age 56)
  • Murdo Gordon, Executive Vice President, Chief Commercial Officer (Age 50)
  • Paul von Autenried, Senior Vice President, Chief Information Officer (Age 55)
  • Anne Nielsen, Senior Vice President, Chief Compliance and Ethics Officer (Age 56)
  • Joseph C. Caldarella, Senior Vice President, Corporate Controller (Age 61)

Who owns Bristol-Myers Squibb stock?

Bristol-Myers Squibb's stock is owned by a number of of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.36%), Bank of Montreal Can (0.28%), Hexavest Inc. (0.09%), Chevy Chase Trust Holdings Inc. (0.09%), Strs Ohio (0.09%) and National Pension Service (0.08%). Company insiders that own Bristol-Myers Squibb stock include Autenried Paul Von, Charles A Bancroft, Giovanni Caforio, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Lewis B Campbell, Louis S Schmukler, Sandra Leung, Theodore R Samuels II and Thomas J Jr Lynch. View Institutional Ownership Trends for Bristol-Myers Squibb.

Who sold Bristol-Myers Squibb stock? Who is selling Bristol-Myers Squibb stock?

Bristol-Myers Squibb's stock was sold by a variety of institutional investors in the last quarter, including First Quadrant L P CA, First Manhattan Co., Strs Ohio, DnB Asset Management AS, Gateway Investment Advisers LLC, Exxonmobil Investment Management Inc. TX, Private Asset Management Inc. and Westpac Banking Corp. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler, Sandra Leung and Thomas J Jr Lynch. View Insider Buying and Selling for Bristol-Myers Squibb.

Who bought Bristol-Myers Squibb stock? Who is buying Bristol-Myers Squibb stock?

Bristol-Myers Squibb's stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Schwab Charles Investment Management Inc., State of Alaska Department of Revenue, Pensionfund DSM Netherlands, Pensionfund Sabic, Hexavest Inc., Creative Planning and Bredin Investment LLC. View Insider Buying and Selling for Bristol-Myers Squibb.

How do I buy Bristol-Myers Squibb stock?

Shares of Bristol-Myers Squibb can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of Bristol-Myers Squibb stock can currently be purchased for approximately $63.43.

How big of a company is Bristol-Myers Squibb?

Bristol-Myers Squibb has a market capitalization of $103.82 billion and generates $19.43 billion in revenue each year. The biopharmaceutical company earns $4.46 billion in net income (profit) each year or $2.54 on an earnings per share basis. Bristol-Myers Squibb employs 25,000 workers across the globe.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 345 PARK AVE, NEW YORK, NY 10154, United States. The biopharmaceutical company can be reached via phone at +1-212-5464000 or via email at [email protected]


MarketBeat Community Rating for Bristol-Myers Squibb (BMY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  698 (Vote Outperform)
Underperform Votes:  653 (Vote Underperform)
Total Votes:  1,351
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bristol-Myers Squibb (NYSE:BMY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.442.442.412.43
Ratings Breakdown: 1 Sell Rating(s)
7 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $65.00$63.92$63.69$63.00
Price Target Upside: 2.72% upside2.41% upside0.48% downside13.99% upside

Bristol-Myers Squibb (NYSE:BMY) Consensus Price Target History

Price Target History for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/22/2018Credit Suisse GroupSet Price TargetHold$62.00LowView Rating Details
1/22/2018BMO Capital MarketsReiterated RatingSell$52.00LowView Rating Details
12/5/2017CitigroupSet Price TargetBuy$72.00LowView Rating Details
10/30/2017SunTrust BanksUpgradeHold -> BuyN/AView Rating Details
10/27/2017Piper Jaffray CompaniesReiterated RatingHold$60.00N/AView Rating Details
10/23/2017Leerink SwannBoost Price TargetOutperform$61.00 -> $72.00N/AView Rating Details
10/16/2017Jefferies GroupDowngradeBuy -> Hold$72.00N/AView Rating Details
10/13/2017BarclaysBoost Price TargetEqual Weight$58.00 -> $65.00N/AView Rating Details
9/19/2017CowenReiterated RatingHold$65.00LowView Rating Details
9/12/2017Hilliard LyonsDowngradeLong-term Buy -> Neutral$65.00LowView Rating Details
9/7/2017Goldman Sachs GroupReiterated RatingBuy$62.00 -> $65.00LowView Rating Details
7/17/2017Deutsche BankSet Price TargetHold$54.00 -> $55.00LowView Rating Details
6/26/2017William BlairReiterated RatingOutperformMediumView Rating Details
4/25/2017Robert W. BairdInitiated CoverageOutperformLowView Rating Details
2/22/2017ArgusReiterated RatingBuy$75.00N/AView Rating Details
2/9/2017GabelliReiterated RatingBuyN/AView Rating Details
1/21/2017JPMorgan Chase & Co.Reiterated RatingBuyN/AView Rating Details
1/8/2017Evercore ISIReiterated RatingHold$55.00N/AView Rating Details
8/25/2016Morgan StanleyReiterated RatingNeutral -> HoldN/AView Rating Details
8/11/2016Berenberg BankDowngradeBuy -> Hold$80.00 -> $70.00N/AView Rating Details
8/11/2016Sanford C. BernsteinReiterated RatingMarket Perform$79.00 -> $65.00N/AView Rating Details
4/6/2016Societe GeneraleInitiated CoverageSell$48.00N/AView Rating Details
(Data available from 1/24/2016 forward)

Earnings

Bristol-Myers Squibb (NYSE:BMY) Earnings History and Estimates Chart

Earnings by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE BMY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018$0.67N/AView Earnings Details
10/26/2017Q3 2017$0.77$0.75$5.20 billion$5.25 billionViewN/AView Earnings Details
7/27/2017Q2 2017$0.73$0.74$5.09 billion$5.14 billionViewN/AView Earnings Details
4/27/2017Q1 2017$0.72$0.84$4.75 billion$4.93 billionViewN/AView Earnings Details
1/26/2017Q416$0.67$0.63$5.14 billion$5.24 billionViewN/AView Earnings Details
10/27/2016Q316$0.65$0.77$4.76 billion$4.83 billionViewListenView Earnings Details
7/28/2016Q216$0.67$0.69$4.60 billion$4.90 billionViewListenView Earnings Details
4/28/2016Q116$0.65$0.74$4.19 billion$4.39 billionViewListenView Earnings Details
1/28/2016Q415$0.28$0.38$4.07 billion$4.29 billionViewListenView Earnings Details
10/27/2015Q315$0.35$0.39$3.83 billion$4.07 billionViewListenView Earnings Details
7/23/2015Q215$0.36$0.53$3.68 billion$4.16 billionViewListenView Earnings Details
4/28/2015Q115$0.50$0.71$3.80 billion$4.04 billionViewN/AView Earnings Details
1/27/2015Q414$0.40$0.46$4.02 billion$4.26 billionViewN/AView Earnings Details
10/24/2014Q314$0.42$0.45$3.80 billion$3.92 billionViewListenView Earnings Details
7/24/2014Q214$0.44$0.48$3.85 billion$3.89 billionViewListenView Earnings Details
4/29/2014Q114$0.43$0.46$3.89 billion$3.81 billionViewListenView Earnings Details
1/24/2014Q413$0.43$0.53$4.30 billion$4.44 billionViewListenView Earnings Details
10/23/2013Q313$0.44$0.46$4.02 billion$4.07 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.45$0.44$4.07 billion$4.05 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.41$0.41$3.88 billion$3.83 billionViewListenView Earnings Details
1/24/2013Q4 2012$0.42$0.47$4.14 billion$4.19 billionViewListenView Earnings Details
10/24/2012$0.42$0.41ViewN/AView Earnings Details
7/25/2012$0.48$0.48ViewN/AView Earnings Details
4/26/2012$0.64$0.64ViewN/AView Earnings Details
1/26/2012$0.55$0.53ViewN/AView Earnings Details
10/27/2011$0.58$0.61ViewN/AView Earnings Details
7/28/2011$0.55$0.56ViewN/AView Earnings Details
4/28/2011$0.53$0.58ViewN/AView Earnings Details
1/27/2011$0.48$0.47ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Bristol-Myers Squibb (NYSE:BMY) Earnings Estimates

2018 EPS Consensus Estimate: $3.08
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.74$0.74$0.74
Q2 20181$0.75$0.75$0.75
Q3 20181$0.78$0.78$0.78
Q4 20181$0.81$0.81$0.81
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Bristol-Myers Squibb (NYSE:BMY) Dividend Information

Next Dividend:2/1/2018
Annual Dividend:$1.60
Dividend Yield:2.52%
Dividend Growth:2.70% (3 Year Average)
Payout Ratio:62.99% (Trailing 12 Months of Earnings)
53.51% (Based on This Year's Estimates)
50.00% (Based on Next Year's Estimates)
Track Record:8 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/7/2017quarterly$0.402.56%1/4/20181/5/20182/1/2018
9/13/2017quarterly$0.392.49%10/5/201710/6/201711/1/2017
6/13/2017quarterly$0.392.86%7/5/20177/7/20178/1/2017
3/2/2017quarterly$0.392.72%4/5/20174/7/20175/1/2017
12/8/2016quarterly$0.392.73%1/4/20171/6/20172/1/2017
8/3/2016quarterly$0.382.02%10/5/201610/7/201611/1/2016
6/7/2016quarterly$0.382.07%6/29/20167/1/20168/1/2016
3/3/2016quarterly$0.382.35%3/30/20164/1/20165/2/2016
12/8/2015quarterly$0.382.22%12/30/20151/4/20162/1/2016
9/17/2015quarterly$0.372.3%9/30/201510/2/201511/2/2015
6/16/2015quarterly$0.372.23%7/1/20157/6/20158/3/2015
3/2/2015quarterly$0.372.39%4/1/20154/6/20155/1/2015
12/9/2014quarterly$0.372.5%12/30/20141/2/20152/2/2015
9/16/2014quarterly$0.362.83%10/1/201410/3/201411/3/2014
6/17/2014quarterly$0.363%7/1/20147/3/20148/1/2014
3/3/2014quarterly$0.362.55%4/2/20144/4/20145/1/2014
12/19/2013quarterly$0.362.7%12/31/20131/3/20142/3/2014
9/17/2013quarterly$0.352.95%10/2/201310/4/201311/1/2013
6/19/2013quarterly$0.353.14%7/2/20137/5/20138/1/2013
3/7/2013quarterly$0.353.74%4/3/20134/5/20135/1/2013
12/4/2012quarterly$0.351/4/20132/1/2013
(Data available from 1/1/2013 forward)

Insider Trades

Bristol-Myers Squibb (NYSE BMY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 69.75%
Insider Trades by Quarter for Bristol-Myers Squibb (NYSE:BMY)
Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE BMY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2017Theodore R Samuels IIDirectorBuy4,000$62.30$249,200.0022,000View SEC Filing  
12/12/2017Thomas J Jr. LynchEVPSell5,300$63.24$335,172.009,251View SEC Filing  
12/4/2017Sandra LeungEVPSell156,582$63.37$9,922,601.34584,373View SEC Filing  
9/6/2017Joseph C CaldarellaSVPSell9,340$60.00$560,400.0046,297View SEC Filing  
8/2/2017Theodore R Samuels IIDirectorBuy6,000$55.94$335,640.0018,000View SEC Filing  
4/7/2017Lamberto AndreottiDirectorSell34,000$53.26$1,810,840.00952,571View SEC Filing  
3/28/2017Lamberto AndreottiDirectorSell34,000$56.17$1,909,780.00986,112View SEC Filing  
3/27/2017Lamberto AndreottiDirectorSell17,000$56.14$954,380.00986,112View SEC Filing  
3/17/2017Louis S SchmuklerInsiderSell5,000$56.49$282,450.0021,483View SEC Filing  
3/15/2017Joseph C CaldarellaSVPSell8,096$57.29$463,819.8455,637View SEC Filing  
3/6/2017Sandra LeungEVPSell92,405$57.02$5,268,933.10488,063View SEC Filing  
2/27/2017Theodore R Samuels IIDirectorBuy12,000$56.77$681,240.0012,000View SEC Filing  
9/8/2016Lamberto AndreottiDirectorSell21,600$56.87$1,228,392.00334,499View SEC Filing  
8/25/2016Lamberto AndreottiDirectorSell23,200$59.17$1,372,744.00364,999View SEC Filing  
7/8/2016Lamberto AndreottiDirectorSell23,200$74.45$1,727,240.00380,099View SEC Filing  
6/28/2016Lamberto AndreottiDirectorSell23,200$72.14$1,673,648.00403,094View SEC Filing  
6/14/2016John E ElickerSVPSell11,820$72.69$859,195.8055,011View SEC Filing  
5/20/2016Charles A BancroftCFOSell30,201$70.79$2,137,928.79184,694View SEC Filing  
5/16/2016Joseph C CaldarellaSVPSell3,519$72.47$255,021.9355,238View SEC Filing  
5/6/2016Sandra LeungEVPSell72,544$70.39$5,106,372.16444,507View SEC Filing  
5/5/2016Lamberto AndreottiDirectorSell23,200$70.54$1,636,528.00425,194View SEC Filing  
5/3/2016Giovanni CaforioCEOSell34,594$71.31$2,466,898.14132,263View SEC Filing  
5/2/2016Autenried Paul VonSVPSell37,258$71.93$2,679,967.94128,463View SEC Filing  
5/2/2016Lamberto AndreottiDirectorSell234,720$71.88$16,871,673.60536,794View SEC Filing  
5/2/2016Louis S SchmuklerInsiderSell22,218$71.95$1,598,585.1021,971View SEC Filing  
4/5/2016Lamberto AndreottiDirectorSell23,200$65.90$1,528,880.00453,094View SEC Filing  
4/4/2016Lamberto AndreottiDirectorSell11,600$65.79$763,164.00453,094View SEC Filing  
3/9/2016Lamberto AndreottiDirectorSell23,200$65.71$1,524,472.00381,254View SEC Filing  
3/8/2016Lewis B CampbellDirectorSell2,500$66.00$165,000.002,500View SEC Filing  
3/4/2016Joseph C CaldarellaSVPSell12,962$64.64$837,863.6846,322View SEC Filing  
2/17/2016Giovanni CaforioCEOSell12,040$63.58$765,503.2076,738View SEC Filing  
2/17/2016Sandra LeungEVPSell10,152$63.57$645,362.64309,547View SEC Filing  
2/12/2016Lamberto AndreottiDirectorSell23,200$59.61$1,382,952.00392,854View SEC Filing  
1/5/2016Lamberto AndreottiDirectorSell23,200$67.56$1,567,392.00310,424View SEC Filing  
1/4/2016Lamberto AndreottiDirectorSell11,600$66.93$776,388.00310,424View SEC Filing  
12/15/2015Lamberto AndreottiDirectorSell23,200$69.03$1,601,496.00332,852View SEC Filing  
11/20/2015Lamberto AndreottiDirectorSell23,200$67.39$1,563,448.00456,052View SEC Filing  
10/6/2015Lamberto AndreottiDirectorSell23,200$60.86$1,411,952.00524,252View SEC Filing  
9/3/2015Lamberto AndreottiDirectorSell23,200$59.40$1,378,080.00546,874View SEC Filing  
6/4/2015Joseph C CaldarellaSVPSell16,972$65.71$1,115,230.12View SEC Filing  
3/16/2015Francis M CussEVPSell114,666$67.81$7,775,501.46View SEC Filing  
3/16/2015Louis S SchmuklerInsiderSell12,000$66.96$803,520.00View SEC Filing  
2/17/2015Sandra LeungGeneral CounselSell11,746$60.39$709,340.94View SEC Filing  
2/12/2015Samuel J MoedSVPSell3,880$59.26$229,928.80View SEC Filing  
2/6/2015Samuel J MoedSVPSell21,478$60.15$1,291,901.70View SEC Filing  
1/29/2015Lamberto AndreottiCEOSell90,246$61.14$5,517,640.44View SEC Filing  
1/29/2015Lewis B CampbellDirectorSell2,500$60.89$152,225.00View SEC Filing  
1/29/2015Louis S SchmuklerInsiderSell5,250$60.73$318,832.50View SEC Filing  
12/5/2014Lamberto AndreottiCEOSell75,000$60.31$4,523,250.00View SEC Filing  
10/24/2014Lamberto AndreottiCEOSell50,000$53.00$2,650,000.00View SEC Filing  
10/6/2014Lamberto AndreottiCEOSell50,000$50.99$2,549,500.00View SEC Filing  
9/16/2014Francis M CussEVPSell63,667$50.77$3,232,373.59View SEC Filing  
9/15/2014Giovanni CaforioCOOSell26,691$49.87$1,331,080.17View SEC Filing  
9/10/2014Joseph C CaldarellaSVPSell7,415$51.03$378,387.45View SEC Filing  
9/8/2014Lamberto AndreottiCEOSell50,000$51.05$2,552,500.00View SEC Filing  
8/19/2014Autenried Paul VonSVPSell20,000$49.89$997,800.00View SEC Filing  
7/29/2014Charles A BancroftCFOSell67,621$51.06$3,452,728.26View SEC Filing  
7/28/2014Samuel J MoedSVPSell25,752$49.32$1,270,088.64View SEC Filing  
3/13/2014Joseph CaldarellaSVPSell9,137$55.20$504,362.4068,965View SEC Filing  
3/10/2014Lamberto AndreottiCEOSell100,000$55.52$5,552,000.00630,783View SEC Filing  
3/10/2014Louis SchmuklerInsiderSell8,799$55.81$491,072.198,861View SEC Filing  
3/5/2014James CorneliusDirectorSell100,000$55.82$5,582,000.00273,393View SEC Filing  
2/28/2014Louis SchmuklerInsiderSell6,088$54.49$331,735.1214,696View SEC Filing  
2/24/2014Giovanni CaforioEVPSell41,563$54.44$2,262,689.7249,753View SEC Filing  
2/19/2014John ElickerSVPSell9,534$54.22$516,933.4832,740View SEC Filing  
2/18/2014Francis CussEVPSell29,800$54.61$1,627,378.00207,237View SEC Filing  
2/14/2014Charles BancroftCFOSell52,963$54.35$2,878,539.0577,303View SEC Filing  
2/14/2014Sandra LeungGeneral CounselSell10,490$54.28$569,397.20195,855View SEC Filing  
2/11/2014Lamberto AndreottiCEOSell86,075$52.66$4,532,709.50500,487View SEC Filing  
2/6/2014Joseph CaldarellaSVPSell35,471$48.90$1,734,531.9059,355View SEC Filing  
2/5/2014Lewis CampbellDirectorSell2,500$48.28$120,700.00View SEC Filing  
2/4/2014James CorneliusDirectorSell100,000$48.90$4,890,000.00373,393View SEC Filing  
7/29/2013James M CorneliusDirectorSell5,000$43.81$219,050.00View SEC Filing  
6/10/2013Autenried Paul VonSVPSell25,000$47.24$1,181,000.00View SEC Filing  
6/6/2013Joseph C CaldarellaSVPSell26,275$46.53$1,222,575.75View SEC Filing  
6/5/2013John E ElickerSVPSell25,997$46.33$1,204,441.01View SEC Filing  
6/4/2013Lamberto AndreottiCEOSell100,000$47.74$4,774,000.00View SEC Filing  
6/4/2013Samuel J MoedSVPSell58,898$47.38$2,790,587.24View SEC Filing  
6/3/2013Elliot SigalEVPSell83,647$48.18$4,030,112.46View SEC Filing  
5/31/2013Beatrice J CazalaEVPSell91,282$47.00$4,290,254.00View SEC Filing  
5/31/2013Giovanni CaforioInsiderSell10,538$47.06$495,918.28View SEC Filing  
5/30/2013Beatrice J CazalaEVPSell22,000$47.00$1,034,000.00View SEC Filing  
5/28/2013Charles A BancroftCFOSell25,000$48.68$1,217,000.00View SEC Filing  
5/28/2013James M CorneliusDirectorSell100,000$47.61$4,761,000.00View SEC Filing  
5/23/2013Beatrice J CazalaEVPSell96,000$46.99$4,511,040.00View SEC Filing  
5/23/2013Giovanni CaforioInsiderSell26,647$46.29$1,233,489.63View SEC Filing  
5/17/2013James M CorneliusDirectorSell225,996$42.99$9,715,568.04View SEC Filing  
5/8/2013James M CorneliusDirectorSell20,000$39.85$797,000.00View SEC Filing  
5/2/2013James M CorneliusDirectorSell20,000$39.76$795,200.00View SEC Filing  
4/11/2013James M CorneliusDirectorSell20,000$41.15$823,000.00View SEC Filing  
3/13/2013James M CorneliusDirectorSell20,000$38.18$763,600.00View SEC Filing  
3/13/2013John E ElickerSVPSell3,409$38.51$131,280.59View SEC Filing  
2/27/2013Giovanni CaforioInsiderSell12,150$37.08$450,522.00View SEC Filing  
2/26/2013James M CorneliusDirectorSell20,000$36.58$731,600.00View SEC Filing  
1/17/2013James M CorneliusDirectorSell20,000$34.33$686,600.00View SEC Filing  
12/28/2012James M CorneliusDirectorSell20,000$32.06$641,200.00View SEC Filing  
10/3/2012James M CorneliusDirectorSell20,000$33.71$674,200.00View SEC Filing  
8/10/2012James M CorneliusDirectorSell10,000$31.81$318,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bristol-Myers Squibb (NYSE BMY) News Headlines

Source:
DateHeadline
Bristol-Myers Squibb (BMY) Given a $62.00 Price Target at Credit Suisse GroupBristol-Myers Squibb (BMY) Given a $62.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - January 23 at 10:46 PM
BRIEF-European Commission Approves Bristol-Myers Squibbs YervoyBRIEF-European Commission Approves Bristol-Myers Squibb's Yervoy
www.reuters.com - January 23 at 12:49 PM
Seattle Genetics' Adcetris Gets EU Nod for Label ExpansionSeattle Genetics' Adcetris Gets EU Nod for Label Expansion
finance.yahoo.com - January 23 at 12:49 PM
Analysts’ Ratings for Nektar Therapeutics in January 2018Analysts’ Ratings for Nektar Therapeutics in January 2018
finance.yahoo.com - January 23 at 12:49 PM
Bristol-Myers Squibbs (BMY) Sell Rating Reaffirmed at BMO Capital MarketsBristol-Myers Squibb's (BMY) Sell Rating Reaffirmed at BMO Capital Markets
www.americanbankingnews.com - January 22 at 7:16 PM
Bristol-Myers (BMY) Reports Data from CheckMate-142 Study - Yahoo FinanceBristol-Myers (BMY) Reports Data from CheckMate-142 Study - Yahoo Finance
finance.yahoo.com - January 22 at 3:33 PM
Bristol-Myers Squibb (BMY) Reports EC Approval for its Yervoy for Treatment of Pediatric Patients 12 Years and Older ... - StreetInsider.comBristol-Myers Squibb (BMY) Reports EC Approval for its Yervoy for Treatment of Pediatric Patients 12 Years and Older ... - StreetInsider.com
www.streetinsider.com - January 22 at 3:33 PM
Zacks: Analysts Anticipate Bristol-Myers Squibb Co (BMY) Will Announce Quarterly Sales of $5.29 BillionZacks: Analysts Anticipate Bristol-Myers Squibb Co (BMY) Will Announce Quarterly Sales of $5.29 Billion
www.americanbankingnews.com - January 22 at 10:36 AM
Bristol-Myers Squibb (BMY) Reports Updated Data for Phase 2 CheckMate -142 Trial Evaluating Opdivo (nivolumab ... - StreetInsider.comBristol-Myers Squibb (BMY) Reports Updated Data for Phase 2 CheckMate -142 Trial Evaluating Opdivo (nivolumab ... - StreetInsider.com
www.streetinsider.com - January 22 at 8:26 AM
Whom Will Pfizer Buy in 2018?Whom Will Pfizer Buy in 2018?
finance.yahoo.com - January 22 at 8:26 AM
Bristol-Myers Squibb (BMY) PT Jumps to $60 At Deutsche Bank - StreetInsider.comBristol-Myers Squibb (BMY) PT Jumps to $60 At Deutsche Bank - StreetInsider.com
www.streetinsider.com - January 21 at 8:12 AM
BMY INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Bristol-Myers Squibb ... - Business Wire (press release)BMY INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Bristol-Myers Squibb ... - Business Wire (press release)
www.businesswire.com - January 20 at 5:28 PM
BMY INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Bristol-Myers Squibb ... - Business Wire (press release)BMY INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Bristol-Myers Squibb ... - Business Wire (press release)
www.businesswire.com - January 20 at 5:28 PM
Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Clinical Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal CancerOpdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Clinical Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer
finance.yahoo.com - January 20 at 5:28 PM
Bristol-Myers Squibb Co (BMY) Expected to Post Earnings of $0.67 Per ShareBristol-Myers Squibb Co (BMY) Expected to Post Earnings of $0.67 Per Share
www.americanbankingnews.com - January 20 at 7:16 AM
Bristol-Myers Squibb (BMY) Upgraded to Hold at Zacks Investment ResearchBristol-Myers Squibb (BMY) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - January 19 at 7:26 PM
BMY INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Bristol-Myers Squibb Company InvestorsBMY INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Bristol-Myers Squibb Company Investors
finance.yahoo.com - January 19 at 5:22 PM
Bear Stearns Commercial Mortgage Securities Trust 2007-PWR15 -- Moodys Affirms Four Classes of BSCMS 2007-PWR15Bear Stearns Commercial Mortgage Securities Trust 2007-PWR15 -- Moody's Affirms Four Classes of BSCMS 2007-PWR15
finance.yahoo.com - January 19 at 11:23 AM
Johnson & Johnson’s Pharmaceutical Segment: 4Q17 EstimatesJohnson & Johnson’s Pharmaceutical Segment: 4Q17 Estimates
finance.yahoo.com - January 19 at 11:23 AM
FY2017 Earnings Forecast for Bristol-Myers Squibb Co (BMY) Issued By Jefferies GroupFY2017 Earnings Forecast for Bristol-Myers Squibb Co (BMY) Issued By Jefferies Group
www.americanbankingnews.com - January 18 at 7:14 AM
FY2018 EPS Estimates for Bristol-Myers Squibb Co Decreased by Analyst (BMY)FY2018 EPS Estimates for Bristol-Myers Squibb Co Decreased by Analyst (BMY)
www.americanbankingnews.com - January 17 at 7:08 PM
The Case For Buying Bristol-Myers SquibbThe Case For Buying Bristol-Myers Squibb
finance.yahoo.com - January 17 at 4:59 PM
Noteworthy Tuesday Option Activity: GILD, WDC, BMYNoteworthy Tuesday Option Activity: GILD, WDC, BMY
www.nasdaq.com - January 16 at 4:52 PM
Can Bristol-Myers Squibb Company’s (NYSE:BMY) ROE Continue To Surpass The Industry Average?Can Bristol-Myers Squibb Company’s (NYSE:BMY) ROE Continue To Surpass The Industry Average?
finance.yahoo.com - January 16 at 4:52 PM
Bristol-Myers Squibb (BMY) CEO Giovanni Caforio Presents at 36th Annual JP Morgan Healthcare Brokers Conference ... - Seeking AlphaBristol-Myers Squibb (BMY) CEO Giovanni Caforio Presents at 36th Annual JP Morgan Healthcare Brokers Conference ... - Seeking Alpha
seekingalpha.com - January 12 at 10:01 AM
Bristol-Myers Squibbs (BMY) 36th Annual JP Morgan Healthcare Brokers Conference (Transcript) - Seeking AlphaBristol-Myers Squibb's (BMY) 36th Annual JP Morgan Healthcare Brokers Conference (Transcript) - Seeking Alpha
seekingalpha.com - January 11 at 10:19 AM
What to Expect from Roche’s Investigational Drug Polatuzumab VedotinWhat to Expect from Roche’s Investigational Drug Polatuzumab Vedotin
finance.yahoo.com - January 10 at 4:52 PM
Bristol-Myers Squibb Co (BMY) Given Consensus Recommendation of "Hold" by AnalystsBristol-Myers Squibb Co (BMY) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - January 8 at 6:02 PM
Bristol-Myers Squibb to Take $3 Billion Charge Related to Tax OverhaulBristol-Myers Squibb to Take $3 Billion Charge Related to Tax Overhaul
www.wsj.com - January 6 at 9:58 AM
[$$] Bristol-Myers Squibb to Take $3 Billion Charge Related to Tax Overhaul[$$] Bristol-Myers Squibb to Take $3 Billion Charge Related to Tax Overhaul
finance.yahoo.com - January 6 at 9:58 AM
 Brokerages Expect Bristol-Myers Squibb Co (BMY) Will Post Quarterly Sales of $5.29 Billion Brokerages Expect Bristol-Myers Squibb Co (BMY) Will Post Quarterly Sales of $5.29 Billion
www.americanbankingnews.com - January 5 at 11:06 AM
[$$] Funding Snapshot: Personal Genome Diagnostics Raises $75 Million Series B[$$] Funding Snapshot: Personal Genome Diagnostics Raises $75 Million Series B
finance.yahoo.com - January 4 at 4:54 PM
EX-Dividend Schedule: Bristol-Myers Squibb Raised its Dividend by 2.6%; Will Trade Ex-Dividend on January 04, 2018EX-Dividend Schedule: Bristol-Myers Squibb Raised its Dividend by 2.6%; Will Trade Ex-Dividend on January 04, 2018
finance.yahoo.com - January 3 at 9:19 AM
Bristol-Myers Squibb to Present at J.P. Morgan Healthcare ConferenceBristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 9:19 AM
4 Reasons to Include Celldex (CLDX) Stock in Your Portfolio - Nasdaq4 Reasons to Include Celldex (CLDX) Stock in Your Portfolio - Nasdaq
www.nasdaq.com - January 2 at 5:54 PM
Should You Buy Bristol-Myers Squibb Stock in 2018?Should You Buy Bristol-Myers Squibb Stock in 2018?
www.fool.com - January 2 at 9:45 AM
Contrasting Bristol-Myers Squibb (BMY) & Patheon (PTHN)Contrasting Bristol-Myers Squibb (BMY) & Patheon (PTHN)
www.americanbankingnews.com - January 1 at 11:32 PM
Bristol-Myers Squibb (BMY) Downgraded by Vetr to "Sell"Bristol-Myers Squibb (BMY) Downgraded by Vetr to "Sell"
www.americanbankingnews.com - December 28 at 1:40 PM
Why Oncology Accounts For 65% Of Bristol-Myers Squibbs ValueWhy Oncology Accounts For 65% Of Bristol-Myers Squibb's Value
www.nasdaq.com - December 27 at 10:27 PM
Read This Before Buying Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming $0.4 DividendRead This Before Buying Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming $0.4 Dividend
finance.yahoo.com - December 27 at 5:25 PM
Bristol-Myers Squibb (BMY) Downgraded by Vetr to "Hold"Bristol-Myers Squibb (BMY) Downgraded by Vetr to "Hold"
www.americanbankingnews.com - December 22 at 10:40 PM
BMY INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Bristol-Myers Squibb ... - Business Wire (press release)BMY INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Bristol-Myers Squibb ... - Business Wire (press release)
www.businesswire.com - December 22 at 7:59 PM
Bristol-Myers Squibb (BMY) Announces Clinical Trial Collaboration with TARIS Biomedical LLC - StreetInsider.comBristol-Myers Squibb (BMY) Announces Clinical Trial Collaboration with TARIS Biomedical LLC - StreetInsider.com
www.streetinsider.com - December 22 at 7:59 PM
Bristol-Myers Squibb (BMY) Announces Clinical Trial Collaboration with TARIS Biomedical LLCBristol-Myers Squibb (BMY) Announces Clinical Trial Collaboration with TARIS Biomedical LLC
www.streetinsider.com - December 21 at 4:55 PM
Bristol-Myers Squibb (BMY) Announces FDA Approval for Opdivo as ... - StreetInsider.comBristol-Myers Squibb (BMY) Announces FDA Approval for Opdivo as ... - StreetInsider.com
www.streetinsider.com - December 21 at 9:59 AM
After Hitting Support, Vetr Issues Buy Rating On Bristol MyersAfter Hitting Support, Vetr Issues Buy Rating On Bristol Myers
finance.yahoo.com - December 21 at 9:59 AM
Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic DiseaseBristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease
finance.yahoo.com - December 20 at 4:52 PM
[$$] Apotex Founder Barry Sherman Was Driven, Generous...and Litigious[$$] Apotex Founder Barry Sherman Was Driven, Generous...and Litigious
finance.yahoo.com - December 20 at 10:02 AM
Is It Time To Sell Bristol-Myers Squibb Company (NYSE:BMY) Based Off Its PE Ratio?Is It Time To Sell Bristol-Myers Squibb Company (NYSE:BMY) Based Off Its PE Ratio?
finance.yahoo.com - December 20 at 10:02 AM
Bristol-Myers Squibb Co (BMY)Bristol-Myers Squibb Co (BMY)
www.reuters.com - December 19 at 10:02 AM

SEC Filings

Bristol-Myers Squibb (NYSE:BMY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bristol-Myers Squibb (NYSE:BMY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bristol-Myers Squibb (NYSE BMY) Stock Chart for Wednesday, January, 24, 2018

Loading chart…

This page was last updated on 1/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.